MUDr. Filip Tylš, Ph.D.
BACKGROUND
I am a psychiatrist and neuroscientist working at the Czech National Institute of Mental Health (NÚDZ), where my patients include those with neurotic and psychotic spectrum disorders. I also participate in psychedelic research (EEG correlates of psychedelic experiences) and, more significantly, in psychedelic-assisted psychotherapy (PAP). In the course of my studies of psychotherapy, I have been influenced by experiences induced by various psychedelic substances, sweat lodges, holotropic breathwork and traditional ayahuasca rituals. I graduated from the 1st Faculty of Medicine, Charles University (2012) and proceeded to complete a PhD programme in Neuroscience at the 3rd Faculty of Medicine (2017), where I became an assistant lecturer. At NÚDZ, I am a member of the team conducting pilot clinical trials of psilocybin administration to human subjects (as a psychedelic sitter). In 2015, together with a group of professional friends, I helped establish the Czech Psychedelic Society (CZEPS); and, since 2017, I have been assisting people manage difficult psychedelic experiences as a member of the Psycare team Additional specialized training courses have included Gestalt Psychotherapy (IVGT Prague; 2014–2020), Psychedelic-Assisted Therapies and Research Certificate Program (CIIS USA; 2018) and MDMA Therapy Training Program for PTSD (MAPS USA; 2019).
WHAT I OFFER
I offer individual psychotherapeutic counselling sessions to both adults and adolescents using the dynamic Gestalt therapy approach. This approach is experience-oriented and is focused on expanding the client’s self-awareness in the here and now, with an emphasis on achieving a unity of mind, emotions, and body. My approach is based on authenticity of contact and reliance on the inner process. I aim to provide a space for self-expression (without judgement) and I partner with my clients on this journey (non-directional coaching), ensuring the confidentiality of this communication and experience. I focus on personality issues, relationship issues and on the understanding and integration of difficult life experiences. To achieve these goals, I employ guided imagery, symbolism and metaphor.
ADDITIONAL INFORMATION
Both long-term cooperation and short-term crisis interventions are possible.
WORK EXPERIENCE:
2012–2015: neuroscientist and psychiatrist (Prague Psychiatric Centre)
2014 to current: psychedelic sitter in pilot clinical trial with psilocybin (healthy volunteers)
2015 to current: neuroscientist and psychiatrist (NÚDZ)
2015–2017: head of the Scientific Section of the Czech Psychedelic Society (CZEPS)
2017 to current: assistant lecturer at the Department of Psychiatry and Medical Psychology (3rd Faculty of Medicine, Charles University)
2017 to current: psychotherapeutic counselling
PROFESSIONAL TRAINING:
2005–2012: 1st Faculty of Medicine, Charles University, Prague (doctor of medicine –MUDr.)
2012–2017: 3rd Faculty of Medicine, Charles University – Neuroscience (PhD); supervisor: MUDr. Tomáš Páleníček, PhD
2013: Speciality course in EEG and epileptology (Neurology Department, Bulovka Hospital)
2012–2013: Participation in Gestalt psychotherapy group for self-experience and personal growth (TERRA)
2014: ECNP Junior scientist Workshop 6–9 March 2014, Nice, France
2014–2020: Training course in Gestalt Psychotherapy (IVGT Prague)
2015: ECNP pilot research internship, Tartu, Estonia, 8–20 February 2015
2015: ECNP School of Neuropsychopharmacology, Oxford, United Kingdom, 5–10 June 2015
2016: Catania International Summer School of Neuroscience, Catania, Sicily
2017: Psychedelic sitter course (Mgr. Vančura, MUDr. Kudrle, Mgr. Odstrčil)
2017: Psilocybin in Research and Therapy workshop in Oakland, California (Dr. Richards, Dr. Guss)
2018: Body work and crisis intervention, 24–25 February 2018 (Dohnal, Dohnalová)
2018: Compass Pathways – Therapist training for COMP_001 study (Psilocybin for treatment-resistant depression), Lisbon, Portugal, 27 April – 1 May 2018
2018–2019: Psychedelic-Assisted Therapies and Research Certificate Program (6 training meetings), CIIS, California, USA
2019: Completion of specialist postgraduate training in Psychiatry
2019: MDMA Therapy Training Program Self-experience part in November 2019 in Boulder, Colorado (Marcela Ot’alora)
AWARDS
Czech Medical Society (ČSL JEP) and Czech Psychiatric Society (ČPS) Travel Award for best presentation, 9–12 June 2016, Špindlerův Mlýn, Czech Republic: F. Tylš, M. Viktorinová, D. Prokopcová, J. Korčák, R. Androvičová, T. Páleníček. The acute effects of psilocybin and their relation to brain activity as measured by quantitative EEG
WFSBP Young investigator Award for best poster at the 10th World Congress of Biological Psychiatry, 29 May – 5 June 2011, Prague: Tyls F., Palenicek T., Fujakova M, Brunovsky M., Horacek J., Krajca V. The role of glutamatergic ionotropic and metabotropic receptors in a model of schizophrenia in rats – effect on behavior, prepulse inhibition and quantitative EEG
PUBLICATIONS (BOOKS AND CHAPTERS):
Tylš F, Páleníček T, Horacek J: Neurobiology of psilocybin effects in relation to its potential therapeutic targets, in Neuropathology of Drug Addictions and Substance Misuse, edited by V.R. Preedy (Kings College London, 2016). (chapter in a book)
Kočárová R, Tylš F: Psychedelická zkušenost a její využití v psychiatrii [Psychedelic experience and its use in psychiatry]. In: Horáček J, Kesner L, Höschl C, Španiel F (eds): Mozek a jeho člověk, mysl a její nemoc. 1. vyd., Galén, Praha 2016. ISBN 978-80-74922-83-1 (chapter in a book)
Tylš F. (2017) The electroencephalographic changes in animal serotonergic model of psychosis – the study of EEG connectivity in relation to behavior (dissertation)
Tylš, F. et al., Fenomén Psychedelie [The Psychedelia Phenomenon], Dybbuk, Prague 2017 (book)
REFERENCES AND RECOMMENDATIONS
Prof. MUDr. Jiří Horáček, PhD, FCMA, Director of Science and Research at NÚDZ, professor at the 3rd Faculty of Medicine, Charles University, jiri.horacek@nudz.cz
William (Bill) A. Richards, M.Div, STM, PhD, psychologist at the Psychiatry Department of the Johns Hopkins School of Medicine, psychotherapist in a private practice (Baltimore), richards3@earthlink.net
PUBLICATIONS (BOOKS AND CHAPTERS):
Tylš, F., Korčák, J., Horáček, J. (2019). Psilocybin: antidepressant and transformative potential [Psilocybin: antidepresivní a transformativní potenciál]. Psychiatrie. 2019, 23(2), 69-76. ISSN 1211-7579.
Korčák, J., Tylš, F., Horáček, J. (2019) Psilocybin: Pharmacology, phenomenology and theory of action [Psilocybin: farmakologie, fenomenologie a teorie účinku]. Psychiatrie. 2019, 23(1), 11-20. ISSN 1211-7579.
Postranecka, Z., Vejmola, C. & Tyls, F. (2019). Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?. Journal of Psychedelic Studies 3(1), 19-31. (no IF)
Tylš F, Brunovsky M, Sulcova K, Kohutova B, Ryznarova Z, Kopecek M. (2019) Latent schizencephaly with psychotic phenotype of schizophrenia with schizencephaly? A case report and review of literature. Clinical EEG & Neuroscience, 50(1), 13-19. IF 2.163
Bravermanová, A., Viktorinová, M., Tylš, F., Novák, T., Androvičová, R., Korčák, J., … & Vlček, P. (2018). Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology, 1-13. IF 3.31
Piorecka, V., Krajca, V., Tyls, F., & Palenicek, T. (2018). Methods for Animal Brain Mapping. Radioengineering, 27(3), 806-812. IF 1.05
Hložek, T., Uttl, L., Kadeřábek, L., Balíková, M., Lhotková, E., Horsley, R. R., … Tylš, F., & Kuchař, M. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC+ CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. European Neuropsychopharmacology, 27(12), 1223-1237. IF 4.24
Androvicova, R., Horacek, J., Tintera, J., Hlinka, J., Rydlo, J., Jezova, D., … Tylš, F & Roman, M. (2017). Individual prolactin reactivity modulates response of nucleus accumbens to erotic stimuli during acute cannabis intoxication: an fMRI pilot study. Psychopharmacology, 1-11. IF 3.54
Páleníček, T., Lhotková, E., Žídková, M., Balíková, M., Kuchař, M., Himl, M., … Tylš F, & Horsley, R. R. (2016). Emerging toxicity of 5, 6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 69, 49-59. IF 1.078
Tylš, F., Pálenícek, T., Kaderábek, L., Lipski, M., Kubešová, A., & Horácek, J. (2016). Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behavioural pharmacology, 27(4), 309-320. IF 2.148
Kubesova, A., Tejkalova, H., Syslova, K., Kacer, P., Vondrousova, J., Tyls, F., Fujakova, M., Palenicek., Horacek, J. (2014). Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology. PloS one, 10(1), e0115439-e0115439. IF 3.230
Fujáková, M., Páleníček, T., Brunovský, M., Gorman, I., Tylš, F., Kubešová, A., Řípová, D., Krajča, V., Horáček, J. The effect of ((−)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis. Pharmacology Biochemistry and Behavior, 2014, roč. 122, č. July, s. 212-221. ISSN: 0091-3057. IF 2,608
Tylš, F., Páleníček, T., Horáček, J. Psilocybin – summary of knowledge and new perspectives. European Neuropsychopharmacology, 2014, roč. 24, č. 3, s. 342-356. ISSN: 0924-977X. IF 4,595
Palenicek T, Fujakova M, Brunovsky M, Horacek J, Gorman I, Balikova M, Rambousek L, Syslova K, Kacer P, Zach P, Bubenikova-Valesova V, Tyls F, Kubesova A, Puskarcikova J, Hoschl C (2012) Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berl) IF 4.077
Páleníček T, Fujáková M, Brunovský M, Balíková M, Horáček J, Gorman I, Tylš F, Tišlerová B, Šoš P, Bubeníková-Valešová V, Höschl C, Krajča V. EEG spectral and coherence analysis of ketamine in rats – correlation with behavioral effects and pharmacokinetics. Neuropsychobiology 2011;63(4):202-218. IF 2.147
Ševčík, L., Tylš, F. Psychedelics as placebo effect amplifiers [Psychedelika jako amplifikátor placebo efektu]. Psychiatrie. 2017, 21(4), 175-180. (in Czech, no IF)
Viktorinová, M., Tylš, F. Unconscious processes of human mind: Insights from psychedelic research [Nevědomé procesy lidské mysli: poznatky z psychedelického výzkumu]. Psychiatrie. 2016, 20(2), 100-107. (in Czech, no IF)
Tylš, F. Neurobiology of the effects of psilocybin in relation to its potential therapeutic targets [Neurobiologie psilocybinu ve vztahu k jeho potenciálnímu terapeutickému využití]. Psychiatrie. 2015, 19(2), 104-112. (in Czech, no IF)
Nováková P., Tylš F., Kubešová A., Kadeřábek L., Fujáková M., Páleníček T. Role of cannabinoids and the cannabinoid system in the induction, neurobiology and therapy of psychotic disorders [Role kanabinoidního systému v indukci, neurobiologii a terapii psychotických onemocnění]. Psychiatrie, 2014; 18 (4): 186-192. (in czech, no IF)
H-index: 7, Times Cited: 168 (21 August 2019)
ORCID 0000-0002-8337-6999
ResearchID C-4542-2018